Molecular Remission Confirmed by Monitoring a <i>PTPN11</i> Mutation in Myeloid Leukemia of Down Syndrome Treated With Reduced‐Intensity Stem Cell Transplantation: A Case Report

The authors declare the following potential conflicts of interest: Y.A. has received consulting fees from Quantdetect, Inc., honoraria from AbbVie and Chugai. S.S.N. receives honoraria from Thermo Fisher Scientific, MSD K.K., Finggal Link Co., Ltd., Nippon Kayaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Iwate Prefecture; research funding from Taiho Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan, LSI Medience Co., Ltd., Qiagen, and Roche Diagnostics; serves as CEO and is a shareholder of Quantdetect, Inc.; receives patent compensation (Patent #6544783, PCT/JP2022/43189) concerning the dPCR primer/probe library OTS-1000ex; and receives research support from Geninus, Array Jet, and Thermo Fisher Scientific. The other authors declare no conflicts of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.